Cantor Fitzgerald Assumes Amicus Therapeutics at Overweight, Raises $20 Price Target

Cantor Fitzgerald analyst Eliana Merle assumes Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and a $20 price target.

Benzinga · 02/04/2020 11:53

Cantor Fitzgerald analyst Eliana Merle assumes Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and a $20 price target.